This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wenning, L. A. Articles by Iwamoto, M. Search for Related Content PubMed PubMed Citation Articles by Wenning, L. A. Articles by Iwamoto, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3253-3258, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00005-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Larissa A. Wenning,^1* Evan J. Friedman,¹ James T. Kost,¹ Sheila A. Breidinger,¹ Jon E. Stek,¹ Kenneth C. Lasseter,² Keith M. Gottesdiener,¹ Joshua Chen,¹ Hedy Teppler,¹ John A. Wagner,¹ Julie A. Stone,¹ and Marian Iwamoto¹

Merck & Co., Inc., Whitehouse Station, New Jersey,¹ Pharmanet Development Group, Inc., Miami, Florida²

Received 2 January 2008/ Returned for modification 9 May 2008/ Accepted 7 July 2008

Raltegravir is a novel human immunodeficiency virus type 1 (HIV-1) integrase inhibitor with potent in vitro activity (95% inhibitory concentration of 31 nM in 50% human serum). This article reports the results of an open-label, sequential, three-period study of healthy subjects. Period 1 involved raltegravir at 400 mg twice daily for 4 days, period 2 involved tenofovir disoproxil fumarate (TDF) at 300 mg once daily for 7 days, and period 3 involved raltegravir at 400 mg twice daily plus TDF at 300 mg once daily for 4 days. Pharmacokinetic profiles were also determined in HIV-1-infected patients dosed with raltegravir monotherapy versus raltegravir in combination with TDF and lamivudine. There was no clinically significant effect of TDF on raltegravir. The raltegravir area under the concentration time curve from 0 to 12 h (AUC_0-12) and peak plasma drug concentration (C_max) were modestly increased in healthy subjects (geometric mean ratios [GMRs], 1.49 and 1.64, respectively). There was no substantial effect of TDF on raltegravir concentration at 12 h postdose (C₁₂) in healthy subjects (GMR [TDF plus raltegravir-raltegravir alone], 1.03; 90% confidence interval [CI], 0.73 to 1.45), while a modest increase (GMR, 1.42; 90% CI, 0.89 to 2.28) was seen in HIV-1-infected patients. Raltegravir had no substantial effect on tenofovir pharmacokinetics: C₂₄, AUC, and C_max GMRs were 0.87, 0.90, and 0.77, respectively. Coadministration of raltegravir and TDF does not change the pharmacokinetics of either drug to a clinically meaningful degree. Raltegravir and TDF may be coadministered without dose adjustments.

---

* Corresponding author. Mailing address: P.O. Box 4, West Point, PA 19486. Phone: (215) 652-4345. Fax: (215) 993-3533. E-mail: Larissa_Wenning{at}merck.com

Published ahead of print on 14 July 2008.

---

Antimicrobial Agents and Chemotherapy, September 2008, p. 3253-3258, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00005-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Anderson, M. S., Kakuda, T. N., Hanley, W., Miller, J., Kost, J. T., Stoltz, R., Wenning, L. A., Stone, J. A., Hoetelmans, R. M. W., Wagner, J. A., Iwamoto, M. (2008). Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects. Antimicrob. Agents Chemother. 52: 4228-4232 [Abstract] [Full Text]